www.jacctctabstracts2014.com

Conclusions: ACT values were not independently associated with in-hospital ischemic or bleeding events or 1-year cardiovascular events in a large population of patients undergoing PCI.

TCT-470

Antithrombotic Therapy during Primary Percutaneous Coronary Intervention for Acute Myocardial Infarction: Insights from Direct Comparison and Mixed Treatment Comparison Analysis of Randomized Trials

Bora Toklu¹, Alexander Volodarskiy², Sripal Bangalore⁻

¹Virginia Commonwealth University, Richmond, VA, ²New York University, New York, NY, ³New York University School of Medicine, New York, United States

Background: In patients with ST-segment elevation myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention (PCI), unfractionated heparin (UFH), low molecular weight heparin (LMWH), fondaparinux, or bivalirudin are treatment options. The relative benefits of each of these regimen merits more systematic investigation.

Methods: We conducted a Medline/EMBASE/CENTRAL search for randomized trials (RCT) comparing parenteral antithrombotic therapies for patients undergoing primary PCI. Five treatment groups were identified: UFH+Glycoprotein IIbIIIa inhibitor (GPI), UFH, bivalirudin, fondaparinux or LMWH+GPI. The primary ischemic outcome was short-term (in-hospital/30-days) major adverse cardiovascular event (MACCE); the primary bleeding outcome was short-term major bleeding.

Results: We identified 23 RCTs that enrolled 22899 patients. In the MTC models, when compared with UFH+GPI, UFH (OR=1.48; 95% CI 1.18-1.86), bivalirudin or fondaparinux (numerically higher) were associated with higher MACCE. Similarly, when compared with LMWH+GPI, UFH (OR=2.63; 95% CI 1.28-5.26), bivalirudin (OR=2.27; 95% CI 1.09-4.76) and fondaparinux (OR=3.12; 95% CI 1.27-7.69) were associated with a higher MACCE. LMWH+GPI, followed by UFH+GPI, bivalirudin, UFH and fondaparinux were the hierarchy for treatment efficacy for MACCE (highest to lowest rank). For bleeding, when compared with UFH+GPI, both UFH (OR=0.70; 95% CI 0.55-0.89) and bivalirudin (OR=0.61; 95% CI 0.47-0.79) were associated with lower major bleeding. Bivalirudin, followed by UFH, LMWH+GPI, UFH+GPI and fondaparinux were the hierarchy for treatment safety (highest to lowest rank). Results were similar in direct comparison meta-analyses: bivalirudin was associated with a 37% increase in MI, 44% increase in urgent revascularization, and an 81% increase in stent thrombosis when compared with UFH or UFH+GPI but with a 43% decrease in major bleeding when compared with UFH+GPI with no difference when compared with UFH alone

Conclusions: In patients undergoing primary PCI, UFH+GPI and LMWH+GPI were most efficacious with the lowest MACCE rate, whereas bivalirudin was safest with the lowest bleeding.

TCT-471

Comparison of Bivalirrudin and Heparin use for Acute Myocardial Infarction: a Meta-Analysis of the Randomized Trials

Mohammad M. Ansari¹, Daniel C. Garcia², Josef L. Toussaint³, Cesar Mendoza⁴, Carlos Alfonso⁵, Mauricio G. Cohen⁶, Alam Schob⁷

¹University of Miami- Jackson Memorial Hospital, Miami, FL, ²University of Miami / Jackson Memorial Hospital, Miami, FL, ³University of Miami, Miami, FL, ⁴Jackson Memorial Hospital, Miami, FL, ⁵University of Miami, Miller School of Medicine, Miami, FL, ⁶University of Miami MIller School of Medicine, Miami, United States, ⁷VA Hospital - Miami, Miami, FL

Background: The use of anticoagulants in the setting of acute myocardial infarction can lead to improvement of short-term survival by costing the increase of bleeding risk. We performed a meta-analysis of all randomized data that has evaluated the clinical outcomes among those patients admitted for acute STEMI and that received either heparin or bivalirudin.

Methods: Pub Med, Chocrane and Scopus were systematically searched up to May 2014. Subjects of analysis were 30 days mortality, AMI, Target Lesion Revascularization, major revascularization, and in-stent thrombosis. We used Fixed or Random Effect analysis using the Cochrane Handbook of Systematic Reviews.

Results: A total of 3 studies provided a total of 7629 patients, being 3804 in the bivalirudin group and 3825 patients in the heparin group. There was a strong trend (p=0.11) towards decreased AMI in the heparin group, with associated significant decrease of TLR and in-stent thrombosis (p< 0.05). Major bleeding trended towards the heparin group (Figure 1).

Conclusions: Our analysis suggests that heparin might be associated with better outcomes at post STEMI event, although there was no mortality benefit. Some of those benefits might be due to decreased in stent thrombosis. Therefore large randomized studies are warranted.

Death	Briefler	and in a	tions	-		Codds Ballin	Ibdde Ratin
Hody or Subgroup Euromas.2010 INEAT PPCL31114 Institutes AML2028	Events 17 46 17	Tenal 2049 015 18079				M-H, Bandore, 95% Cr	M-R. Bandum, 92% CI
total (93% CD		1804			100.05	8.30 (0.41, 1.2N)	
futial evenity teterogeneity: Tau* - fact for evenal effect				119-	8.111.1	- 483	6.03 P.1 Paulo Favora Heparte
AMI	1000	22				C.23332437	
Inedy or Subgroup	Division Events	Facial	Evenus		Westurnet.	Oddx Ralis H-H, Racidore, 95%-CI	Mont Random, 95% Cl
Excumate 2013 HEAT PRC12014 Horonom AMIL2028	(3 24 33	915 915	2.0 .8 .12			1.99 (0.96, 4.72) 3.05 (5.36, 6.83) 5.03 (0.83, 5.68)	
Tetal (9115 Ci)	76	1.80.4	50		100.8%	1.72 (0.88, 3.34)	-
Parteringenerally Taur's	11.2.2 (3		8.7, 49 4		8.481.7	- 895	10.02 0.1 00 100 Fauth's Resolvation Faust's Departs
TLR	Breathe		Parana	21		Othin Batte	Odulta Katisa
itudu er Sobgring	Events	Varial	Everate	Terial		H-H, Racidson, 95% C	Month Random, Stirk Cl.
Foroman 2013	29	1049	21	5109	11.6%	3.42.05.88, 2.581 4.0811.66, 10.021	
Instrume AML2018	47	1.800	- 15		41.85	1.35 (0.47, 7.11)	
Fortal (WIN CO Family events	300	1004	+2		100.01	1.77 [1.02, 9.06]	•
Returnering Tau? - Test for postal effect				3.00 -	8.093.7	= 5 90	5.01 6.1 EB 100 Favors Montrollin Founts Pagares
Major Bleedin							
	Sivality.		Hegus			Outlife Runito	Outsite Nutrice
Mady or Saleproup	Exercite 2.0	Turkall	Events 4.7	Tatal Line	3-2.12%	0.41 (0.26. 0.64)	H-H, Kandson, WIN CI
HEAT PPICI 20114 Turingen ANE 20108	82	913	2.8	914 1887	28.55	1.15 (0.64, 1.82) (0.58 (0.64, 0.76)	
Fotal (95% Cl)	140	1004		1548	100.0%	0.03 (0.39, 1.04)	•
telerogeneily. Tad' - feet for overall effect				1.1 F = 1	0.011 f =		1.03 0.3 Termur's Rivellington, Passingto Versionton
In-stent							
Thrombosis	Elivatire Exercits	tint of	Harris		and the second	Odds Ratter M-H, Randoon, 95% CI	Oulds Ratio N-H, Randson, 9310-C1
HAT PPEJ 2018 HEAT PPEJ 2014 Turtrism, AMS 2008	4.3 2.5 55	1089	*	1109 10 1802	23.818 28.79 47.99	3 30 11.33, 7.42 3.90 11.38, 9.83 1.60 (0.84, 2.75)	
Fortal (90% CD Tunal assessio		3804	1.14	3825	100.05	2.37 (3.25, 4.26)	•
tateringeneity Tauf' -	0.10.03					- 384	b.m. m. 10 100

Pharmacotherapy - GPIIb/IIIa inhibitors Washington Convention Center, Lower Level, Hall A Saturday, September 13, 2014, 5:00 PM-7:00 PM

Abstract nos: 472-473

TCT-472

Impact of Excess Dosing of Eptifibatide During PCI for ACS: A Pooled Analysis from the HORIZONS-AMI and ACUITY Trials

Mahesh V. Madhavan¹, Philippe Genereux², Ke Xu³, Ovidiu Dressler³, Roxana Mehran⁴, Gregg W. Stone²

¹Columbia University Medical Center, New York, NY, ²Columbia University Medical Center and the Cardiovascular Research Foundation, New York, NY,

³Cardiovascular Research Foundation, New York, NY, ⁴Icahn School of Medicine at Mount Sinai, New York, NY

Background: Excess dosing of antithrombotic agents has been associated with adverse outcomes. To date, dosing errors have not been studied in pts specifically undergoing percutaneous coronary intervention (PCI) for acute coronary syndromes (ACS)

Methods: Analysis was performed in pts who received recommended (labeled dosing) vs. excess eptifibatide bolus or infusion doses during PCI in the HORI-ZONS-AMI and ACUITY trials. Adverse outcome rates were assessed. Multivariable analysis was performed to determine predictors of excess dosing and adverse events.

Results: Of 5,287 pts (840 STEMI, 4,447 NSTEACS) treated with eptifibatide, 543 (10.3%) were administered doses outside the recommended range (including in 319 of 574 pts (56%) with renal dysfunction [creatinine clearance < 50 mL/min]. Predictors of excess dosing included STEMI presentation, baseline creatinine clearance, baseline hematocrit, and hypertension. Pts who received excess dosing experienced higher rates of adverse outcomes (Table). By multivariable analysis, excess dosing was independently associated with 30-day non-CABG major bleeding (HR [95%CI] = 1.38 [1.05, 1.82], p=0.02) but not 30-day or 1-year all-cause mortality (HR [95%CI] = 1.47 [0.79, 2.74], p=0.22, and 1.26 [0.84, 1.88], p=0.27, respectively].

Conclusions: In this large-scale study, excess dosing of eptifibatide during PCI for ACS was common (even in the clinical trial setting), and was an independent predictor of major bleeding but not early or late mortality. Quality control efforts to ensure proper dosing may improve outcomes in high-risk ACS pts.